SIETES :: 92718 citas

Resultados de la búsqueda por AMOXICILINA REFINAR BÚSQUEDA

1.

Chua K-P, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ 2019;364:16 de enero. [Ref.ID 103048]

2.

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]

3.

Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. A review. JAMA 2019;321:15 de enero. [Ref.ID 103008]

4.

Lovegrove MC, Geller AI, Fleming-Dutra KE, Shehab N, Sapiano MRP, Budnitz DS. US emergency department visits for adverse drug events from antibiotics in children, 2011–2015. J Pediatric Infect Dis Soc 2018:23 de agosto. [Ref.ID 102811]

5.

Anónimo. Pneumonies communautaires peu graves chez les enfants. Prescrire 2018;38:518-23. [Ref.ID 102764]

6.

Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]

7.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

8.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

9.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

10.

Gisbert JP, Molina-Infante J. Tratamiento actual de la infección por Helicobacter pylori. Med Clin (Barc) 2017;148:20-2. [Ref.ID 101339]

11.

Liou J-M, Fang Y-J, Chen C-C, Bair M-J, Chang C-Y, Lee Y-C, Chen M-J, Tseng C-H, Hsu Y-C, Lee J-Y, Yang T-H, Luo J-C, Chang C-C, Chen Y-N, Sheu B-S, Lin J-T, Wu J-Y, El-Omar EM, Wu M-S, Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016;388:2355-65. [Ref.ID 100981]

12.

Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M. Comparación de cuádruple terapia concomitante sin bismuto con triple terapia clásica como primera línea de tratamiento para la erradicación del Helicobacter pylori. Med Clin (Barc) 2016;147:199-201. [Ref.ID 100727]

13.

Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D. ß-lactams against tuberculosis — New trick for an old dog?. N Engl J Med 2016;375:393-4. [Ref.ID 100492]

14.

Anónimo. Alternatives to fluoroquinolones. Med Lett Drugs Ther 2016;58:75-6. [Ref.ID 100457]

15.

Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]

16.

Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]

17.

Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, Quaratino D. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015;136:685-91. [Ref.ID 99527]

18.

Li B-Z, Threapleton DE, Wang JY, Xu J-M, Yuan J-Q, Zhang C, Li P, Ye Q-L, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052. [Ref.ID 99413]

19.

Braden B. The best and worst treatments for Helicobacter pylori. BMJ 2015;351:h4146. [Ref.ID 99411]

20.

Anónimo. Ceftobiprole médocaril. Prescrire 2015;35:331-5. [Ref.ID 99133]